ClinicalTrials.gg
CompletedNCT00368966Updated Aug 16, 2012Results posted

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.

A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine and 7-valent Pneumococcal Conjugate Vaccine in Vaccines, Pneumococcal, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 41 sites in Spain. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-08-16.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
619
Allocation
Randomized
Ages
42 Days to 98 Days
Sex
All
01

Study summary

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine pediatric vaccinations in Spain.

02

Conditions studied

  • Vaccines, Pneumococcal

Keywords

  • Pneumococcal
  • Pediatric
  • Vaccine
03

In context

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
42 Days to 98 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy 2-month-old infants
  • Available for the entire study period

Exclusion criteria

Exclusion criteria:

  • Previous vaccination with any vaccine before the start of the study
  • Known to vaccination
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
619 participants (actual)

Study arms

  • Experimental
    1

    Biological: 13-valent Pneumococcal Conjugate Vaccine

  • Active comparator
    2

    Biological: 7-valent Pneumococcal Conjugate Vaccine

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Predefined Meningococcal C Serum Bactericidal Assay (SBA) Titer of ≥ 1:8, and a Predefined Antibody Level for Diphtheria in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series

    Percentage of participants achieving predefined antibody threshold levels; greater than or equal to (≥) 1:8 for meningococcal C SBA titer and ≥ 0.10 or \>=0.01 International Units Per Milliliter (IU/mL) for diphtheria along with the corresponding 95% Confidence Interval (CI) are presented.

    Time frame: One month after 2-doses of the infant series (5 months of age)

  2. Geometric Mean Titer (GMT) of Meningococcal C in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series

    Time frame: One month after 2-doses of the infant series (5 months of age)

  3. Geometric Mean Antibody Concentration (GMC) for Diphtheria in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series

    Time frame: One month after 2-doses of the infant series (5 months of age)

  4. Percentage of Participants Reporting Pre-Specified Local Reactions

    Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig) (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.

    Time frame: During the 4-day period after each dose

  5. Percentage of Participants Reporting Pre-Specified Systemic Events

    Systemic events (fever \[Fv\] ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased \[Decr\] appetite, irritability, increased \[Incr\] sleep, decreased sleep, hives, use of medication \[Med\] to treat symptoms \[sx\], and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: During the 4-day period after each dose

  6. Geometric Mean Antibody Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Group After the Second Dose and After the Third Dose of a 3-Dose Infant Series and After the Toddler Dose

    GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes which are present in both 7vPnC and 13vPnC (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)

  7. Percentage of Participants Achieving Predefined Antibody Levels for Pertussis, Diphtheria, Tetanus, and Poliovirus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose

    Percentage of participants achieving predefined antibody threshold levels with the corresponding 95% CI for each concomitant antigen (pertussis antigens including Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA), and Pertactin (PRN); diphtheria; tetanus; and poliovirus types 1, 2, and 3) are presented.

    Time frame: One month after the 3-dose infant series (7 months of age) and the toddler dose (16 months of age)

  8. Geometric Mean Titers (GMT) for Poliovirus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose

    Time frame: One month after the 3-dose infant series (7 months of age) and the toddler dose (16 months of age)

  9. Geometric Mean Antibody Concentrations (GMC) for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose

    Time frame: One month after the 3-dose infant series (7 months of age) and the toddler dose (16 months of age)

  10. Geometric Mean Antibody Concentrations (GMC) for Pertussis in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose

    GMCs with the corresponding 95% CI for each concomitant antigen pertussis antigens (PT, FHA, PRN, and FIM) as measured by EU/mL are presented.

    Time frame: One month after the 3-dose infant series (7 months of age) and the toddler dose (16 months of age)

  11. Percentage of Participants Achieving Antibody Level ≥ 0.35 Microgram Per Milliliter (μg/mL) in 13vPnC Group After the Second Dose and After the Third Dose of a 3-Dose Infant Series and After the Toddler Dose

    Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes, present in both 13vPnC and 7vPnC (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)

07

Results

Posted Aug 16, 2012

Participant flow

Participants were recruited in Spain from October 2006 to December 2006.

Infant Series
Participant flow — Infant Series
Milestone13vPnC7vPnC
Started315304
Vaccinated dose 1314302
Vaccinated dose 2307298
Vaccinated dose 3301296
Completed299294
Not completed1610
Withdrew: Withdrawal by subject116
Withdrew: Protocol violation21
Withdrew: Lost to follow-up20
Withdrew: Randomization error01
Withdrew: Failed to meet eligibility criteria01
Withdrew: Adverse event01
Withdrew: Failed to return10
After Infant
Participant flow — After Infant
Milestone13vPnC7vPnC
Started299294
Completed293289
Not completed65
Withdrew: Failed to return31
Withdrew: Adverse event12
Withdrew: Withdrawal by subject11
Withdrew: Death10
Withdrew: Lost to follow-up01
Toddler Dose
Participant flow — Toddler Dose
Milestone13vPnC7vPnC
Started293289
Completed292286
Not completed13
Withdrew: Withdrawal by subject11
Withdrew: Lost to follow-up02

Outcome measures

PrimaryPercentage of Participants Achieving Predefined Meningococcal C Serum Bactericidal Assay (SBA) Titer of ≥ 1:8, and a Predefined Antibody Level for Diphtheria in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series

Percentage of participants achieving predefined antibody threshold levels; greater than or equal to (≥) 1:8 for meningococcal C SBA titer and ≥ 0.10 or \>=0.01 International Units Per Milliliter (IU/mL) for diphtheria along with the corresponding 95% Confidence Interval (CI) are presented.

Time frame:
One month after 2-doses of the infant series (5 months of age)
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Predefined Meningococcal C Serum Bactericidal Assay (SBA) Titer of ≥ 1:8, and a Predefined Antibody Level for Diphtheria in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series
Percentage of Participants13vPnC7vPnC
Meningococcal C ≥ 1:898.3 (96.1 to 99.5)98.9 (96.9 to 99.8)
Diptheria ≥ 0.10 IU/mL95.9 (93.0 to 97.9)94.7 (91.4 to 97.0)
Diptheria ≥ 0.01 IU/mL100.0 (98.8 to 100.0)100.0 (98.7 to 100.0)
Statistical analysis
  • 13vPnC vs 7vPnC · Difference: -0.6 · 95% CI -2.9 to 1.6
  • 13vPnC vs 7vPnC · Difference: 1.2 · 95% CI -2.3 to 4.9
  • 13vPnC vs 7vPnC · Difference: 0.0 · 95% CI -1.3 to 1.3
PrimaryGeometric Mean Titer (GMT) of Meningococcal C in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series
Time frame:
One month after 2-doses of the infant series (5 months of age)
Reported as:
Geometric mean · titer
Geometric Mean Titer (GMT) of Meningococcal C in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series
titer13vPnC7vPnC
Geometric Mean Titer (GMT) of Meningococcal C in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series191.22 (167.72 to 218.02)266.19 (234.86 to 301.71)
Statistical analysis
  • 13vPnC vs 7vPnC · Ratio: 0.72 · 95% CI 0.60 to 0.86
PrimaryGeometric Mean Antibody Concentration (GMC) for Diphtheria in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series
Time frame:
One month after 2-doses of the infant series (5 months of age)
Reported as:
Geometric mean · IU/mL
Geometric Mean Antibody Concentration (GMC) for Diphtheria in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series
IU/mL13vPnC7vPnC
Geometric Mean Antibody Concentration (GMC) for Diphtheria in 13vPnC Group Relative to 7vPnC Group After 2-doses of the Infant Series0.51 (0.47 to 0.57)0.63 (0.57 to 0.70)
Statistical analysis
  • 13vPnC vs 7vPnC · Ratio: 0.81 · 95% CI 0.70 to 0.94
PrimaryPercentage of Participants Reporting Pre-Specified Local Reactions

Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (Sig) (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.

Time frame:
During the 4-day period after each dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions
percentage of participants13vPnC Dose 17vPnC Dose 113vPnC Dose 27vPnC Dose 213vPnC Dose 37vPnC Dose 313vPnC Toddler Dose7vPnC Toddler Dose
Tenderness-Any (n=275,270,227,232,217,215,193,170)49.543.345.446.647.941.964.264.7
Tenderness-Sig (n=247,250,192,203,181,171,136,1182.82.84.23.96.10.05.96.8
Swelling-Any (n=252,254,206,212,203,181,153,140)19.014.228.223.127.628.233.330.7
Swelling-Mild (n=251,254,206,212,201,186,151,132)16.314.225.720.326.425.831.124.2
Swelling-Mod (n=247,248,191,201,180,173,136,124)4.91.65.84.55.64.011.812.9
Swelling-Severe(n=246,247,191,201,176,171,131,113)0.00.00.00.00.00.00.00.0
Redness-Any (n=255,251,211,217,203,198,159,146)22.019.134.130.931.034.840.941.1
Redness-Mild (n=254,251,210,215,203,195,157,141)20.118.332.430.229.133.335.037.6
Redness-Mod (n=247,247,192,203,177,175,137,120)2.41.23.12.54.55.113.112.5
Redness-Severe (n=246,247,191,201,176,171,131,113)0.00.00.00.00.00.00.00.0
PrimaryPercentage of Participants Reporting Pre-Specified Systemic Events

Systemic events (fever \[Fv\] ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased \[Decr\] appetite, irritability, increased \[Incr\] sleep, decreased sleep, hives, use of medication \[Med\] to treat symptoms \[sx\], and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
During the 4-day period after each dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events
percentage of participants13vPnC Dose 17vPnC Dose 113vPnC Dose 27vPnC Dose 213vPnC Dose 37vPnC Dose 313vPnC Toddler Dose7vPnC Toddler Dose
Fv≥38°C, ≤39°C (n=262,253,213,223,198,196,162,145)30.524.540.441.734.338.338.944.8
Fv>39°C, ≤40°C (n=249,247,194,204,177,174,135,118)0.80.82.62.55.65.28.16.8
Fv >40°C (n=249,247,192,201,176,171,132,113)0.00.00.00.00.00.00.80.0
Decr appetite (n=269,258,226,229,219,204,174,147)39.836.845.144.547.042.653.447.6
Irritability (n=276,267,234,244,229,221,183,170)51.442.764.561.557.258.861.761.8
Incr sleep (n=273,269,218,221,206,203,160,145)53.551.346.841.633.534.539.435.2
Decr sleep (n=263,255,218,223,205,190,151,129)34.624.736.229.630.225.827.227.1
Med-treat sx (n=267,256,232,243,216,209,176,163)50.646.960.361.355.655.559.760.1
Med-prevent sx (n=269,258,231,237,222,211,178,159)49.147.758.458.656.353.659.661.6
PrimaryGeometric Mean Antibody Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Group After the Second Dose and After the Third Dose of a 3-Dose Infant Series and After the Toddler Dose

GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes which are present in both 7vPnC and 13vPnC (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)
Reported as:
Geometric mean · μg/mL
Geometric Mean Antibody Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in 13vPnC Group After the Second Dose and After the Third Dose of a 3-Dose Infant Series and After the Toddler Dose
μg/mL13vPnC After Infant Series Dose 213vPnC After Infant Series Dose 313vPnC After the Toddler Dose
Common Serotype - Serotype 4 (n=269,269,241)1.89 (1.70 to 2.10)2.33 (2.11 to 2.57)4.97 (4.42 to 5.58)
Common Serotype - Serotype 6B (n=267,267,228)0.42 (0.37 to 0.47)3.88 (3.41 to 4.41)11.88 (10.57 to 13.35)
Common Serotype - Serotype 9V (n=273,273,241)1.49 (1.34 to 1.66)1.71 (1.56 to 1.86)3.44 (3.12 to 3.80)
Common Serotype - Serotype 14 (n=270,270,230)3.84 (3.37 to 4.37)6.17 (5.45 to 6.98)11.37 (10.17 to 12.71)
Common Serotype - Serotype 18C (n=267,267,239)1.58 (1.40 to 1.78)2.29 (2.08 to 2.52)3.96 (3.55 to 4.43)
Common Serotype - Serotype 19F (n=270,270,231)2.85 (2.53 to 3.21)2.64 (2.42 to 2.89)8.04 (7.07 to 9.14)
Common Serotype - Serotype 23F (n=260,260,233)0.54 (0.47 to 0.62)2.15 (1.89 to 2.45)5.07 (4.50 to 5.71)
Additional Serotype - Serotype 1 (n=268,268,235)1.90 (1.70 to 2.13)3.04 (2.73 to 3.38)4.79 (4.21 to 5.45)
Additional Serotype - Serotype 3 (n=267,267,243)0.79 (0.72 to 0.87)0.97 (0.87 to 1.08)1.07 (0.95 to 1.20)
Additional Serotype - Serotype 5 (n=261,261,234)0.99 (0.90 to 1.10)1.93 (1.74 to 2.13)3.90 (3.53 to 4.31)
Additional Serotype - Serotype 6A (n=269,269,235)1.10 (0.97 to 1.25)3.16 (2.82 to 3.53)7.07 (6.35 to 7.87)
Additional Serotype - Serotype 7F (n=268,268,242)1.85 (1.69 to 2.02)4.03 (3.70 to 4.40)5.78 (5.13 to 6.53)
Additional Serotype - Serotype 19A (n=267,267,226)2.36 (2.10 to 2.66)3.07 (2.79 to 3.37)11.64 (10.43 to 13.00)
Statistical analysis
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 1.23 · 95% CI 1.13 to 1.35
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 9.28 · 95% CI 8.18 to 10.53
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 1.15 · 95% CI 1.05 to 1.25
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 1.61 · 95% CI 1.41 to 1.83
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 1.45 · 95% CI 1.30 to 1.61
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 0.93 · 95% CI 0.83 to 1.03
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 4.00 · 95% CI 3.55 to 4.50
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 1.60 · 95% CI 1.46 to 1.76
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 1.23 · 95% CI 1.13 to 1.35
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 1.94 · 95% CI 1.78 to 2.11
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 2.87 · 95% CI 2.58 to 3.20
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 2.18 · 95% CI 1.98 to 2.41
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 1.30 · 95% CI 1.18 to 1.44
PrimaryPercentage of Participants Achieving Predefined Antibody Levels for Pertussis, Diphtheria, Tetanus, and Poliovirus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose

Percentage of participants achieving predefined antibody threshold levels with the corresponding 95% CI for each concomitant antigen (pertussis antigens including Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA), and Pertactin (PRN); diphtheria; tetanus; and poliovirus types 1, 2, and 3) are presented.

Time frame:
One month after the 3-dose infant series (7 months of age) and the toddler dose (16 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Predefined Antibody Levels for Pertussis, Diphtheria, Tetanus, and Poliovirus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose
percentage of participants13vPnC After Infant Series7vPnC After Infant Series13vPnC After the Toddler Dose7vPnC After the Toddler Dose
Pertussis, PT ≥ 5.0 EU/mL100.0 (98.7 to 100.0)100.0 (98.7 to 100.0)99.6 (98.0 to 100.0)99.6 (97.9 to 100.0)
Pertussis, PT (Infant ≥ 20; Toddler ≥ 11) EU/mL93.2 (89.7 to 95.8)95.1 (91.9 to 97.3)94.9 (91.6 to 97.2)96.3 (93.3 to 98.2)
Pertussis, FHA ≥ 5.0 EU/mL100.0 (98.7 to 100.0)100.0 (98.7 to 100.0)100.0 (98.7 to 100.0)100.0 (98.6 to 100.0)
Pertussis, FHA ≥ 7.82 EU/mL100.0 (98.7 to 100.0)100.0 (98.7 to 100.0)100.0 (98.7 to 100.0)100.0 (98.6 to 100.0)
Pertussis, FHA (Infant ≥ 64; Toddler ≥ 99) EU/mL93.9 (90.5 to 96.3)95.1 (91.9 to 97.3)94.5 (91.1 to 96.9)95.1 (91.8 to 97.4)
Pertussis, PRN ≥ 5 EU/mL100.0 (98.7 to 100.0)100.0 (98.7 to 100.0)100.0 (98.7 to 100.0)100.0 (98.6 to 100.0)
Pertussis, PRN (Infant ≥ 39; Toddler ≥ 69) EU/mL94.5 (91.3 to 96.8)95.1 (91.9 to 97.3)93.5 (89.9 to 96.1)95.2 (91.9 to 97.4)
Diptheria ≥ 0.10 IU/mL99.3 (97.5 to 99.9)100.0 (98.7 to 100.0)99.2 (97.2 to 99.9)100.0 (98.5 to 100.0)
Diptheria ≥ 0.01 IU/mL100.0 (98.7 to 100.0)100.0 (98.7 to 100.0)100.0 (98.6 to 100.0)100.0 (98.5 to 100.0)
Tetanus ≥ 0.10 IU/mL98.6 (96.3 to 99.6)98.2 (95.8 to 99.4)98.6 (95.9 to 99.7)97.8 (94.9 to 99.3)
Tetanus ≥ 0.01 IU/mL100.0 (98.7 to 100.0)100.0 (98.7 to 100.0)100.0 (98.3 to 100.0)100.0 (98.4 to 100.0)
Poliovirus, Type 1 ≥ 1:8100.0 (98.7 to 100.0)100.0 (98.7 to 100.0)100.0 (98.6 to 100.0)100.0 (98.6 to 100.0)
Poliovirus, Type 2 ≥ 1:8100.0 (98.7 to 100.0)99.3 (97.5 to 99.9)100.0 (98.6 to 100.0)99.6 (97.8 to 100.0)
Poliovirus, Type 3 ≥ 1:8100.0 (98.7 to 100.0)99.6 (98.0 to 100.0)100.0 (98.6 to 100.0)100.0 (98.6 to 100.0)
Statistical analysis
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Difference: 0.0 · 95% CI -1.3 to 1.3
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Difference: -1.9 · 95% CI -6.0 to 2.0
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Difference: 0.0 · 95% CI -1.3 to 1.3
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Difference: 0.0 · 95% CI -1.3 to 1.3
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Difference: -1.3 · 95% CI -5.2 to 2.6
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Difference: 0.0 · 95% CI -1.3 to 1.3
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Difference: -0.6 · 95% CI -4.4 to 3.2
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: 0.0 · 95% CI -1.7 to 1.7
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: -1.4 · 95% CI -5.1 to 2.2
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: 0.0 · 95% CI -1.4 to 1.4
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: 0.0 · 95% CI -1.4 to 1.4
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: -0.6 · 95% CI -4.6 to 3.3
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: 0.0 · 95% CI -1.4 to 1.4
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: -1.7 · 95% CI -5.8 to 2.3
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Difference: -0.7 · 95% CI -2.5 to 0.7
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Difference: 0.0 · 95% CI -1.3 to 1.3
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: -0.8 · 95% CI -2.8 to 0.8
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: 0.0 · 95% CI -1.5 to 1.5
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Difference: 0.4 · 95% CI -2.1 to 2.9
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Difference: 0.0 · 95% CI -1.3 to 1.3
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: 0.8 · 95% CI -2.1 to 3.8
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: 0.0 · 95% CI -1.8 to 1.7
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Difference: 0.0 · 95% CI -1.4 to 1.3
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Difference: 0.7 · 95% CI -0.6 to 2.6
  • 13vPnC After Infant Series vs 7vPnC After Infant Series · Difference: 0.4 · 95% CI -1.0 to 2.0
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: 0.0 · 95% CI -1.5 to 1.5
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: 0.4 · 95% CI -1.1 to 2.2
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: 0.0 · 95% CI -1.5 to 1.5
PrimaryGeometric Mean Titers (GMT) for Poliovirus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose
Time frame:
One month after the 3-dose infant series (7 months of age) and the toddler dose (16 months of age)
Reported as:
Geometric mean · titer
Geometric Mean Titers (GMT) for Poliovirus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose
titer13vPnC After Infant Series Dose 37vPnC After Infant Series Dose 313vPnC After the Toddler Dose7vPnC Afte the Toddler Dose
Poliovirus Type 1436.98 (378.21 to 504.88)436.15 (378.17 to 503.02)1057.40 (939.06 to 1190.70)1286.70 (1131.00 to 1463.80)
Poliovirus Type 2266.34 (227.84 to 311.36)281.85 (240.04 to 330.94)1032.30 (912.96 to 1167.10)1141.10 (992.96 to 1311.40)
Poliovirus Type 3897.67 (766.30 to 1051.60)943.95 (806.71 to 1104.50)2571.10 (2249.40 to 2938.90)2410.80 (2106.70 to 2758.80)
Statistical analysis
  • 13vPnC After Infant Series Dose 3 vs 7vPnC After Infant Series Dose 3 · Ratio: 1.00 · 95% CI 0.82 to 1.23
  • 13vPnC After Infant Series Dose 3 vs 7vPnC After Infant Series Dose 3 · Ratio: 0.94 · 95% CI 0.76 to 1.18
  • 13vPnC After Infant Series Dose 3 vs 7vPnC After Infant Series Dose 3 · Ratio: 0.95 · 95% CI 0.76 to 1.19
  • 13vPnC After the Toddler Dose · Ratio: 0.82 · 95% CI 0.69 to 0.98
  • 13vPnC After the Toddler Dose vs 7vPnC Afte the Toddler Dose · Ratio: 0.90 · 95% CI 0.75 to 1.09
  • 13vPnC After the Toddler Dose vs 7vPnC Afte the Toddler Dose · Ratio: 1.07 · 95% CI 0.88 to 1.29
PrimaryGeometric Mean Antibody Concentrations (GMC) for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose
Time frame:
One month after the 3-dose infant series (7 months of age) and the toddler dose (16 months of age)
Reported as:
Geometric mean · IU/mL
Geometric Mean Antibody Concentrations (GMC) for Diphtheria and Tetanus in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose
IU/mL13vPnC After Infant Series Dose 37vPnC After Infant Series Dose 313vPnC After the Toddler Dose7vPnC Afte the Toddler Dose
Diphtheria1.19 (1.08 to 1.30)1.40 (1.28 to 1.53)3.00 (2.65 to 3.40)3.51 (3.08 to 3.99)
Tetanus0.90 (0.80 to 1.01)0.87 (0.79 to 0.97)1.63 (1.38 to 1.91)1.45 (1.24 to 1.69)
Statistical analysis
  • 13vPnC After Infant Series Dose 3 vs 7vPnC After Infant Series Dose 3 · Ratio: 0.85 · 95% CI 0.75 to 0.96
  • 13vPnC After Infant Series Dose 3 vs 7vPnC After Infant Series Dose 3 · Ratio: 1.03 · 95% CI 0.88 to 1.20
  • 13vPnC After the Toddler Dose vs 7vPnC Afte the Toddler Dose · Ratio: 0.86 · 95% CI 0.71 to 1.02
  • 13vPnC After the Toddler Dose vs 7vPnC Afte the Toddler Dose · Ratio: 1.12 · 95% CI 0.90 to 1.40
PrimaryGeometric Mean Antibody Concentrations (GMC) for Pertussis in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose

GMCs with the corresponding 95% CI for each concomitant antigen pertussis antigens (PT, FHA, PRN, and FIM) as measured by EU/mL are presented.

Time frame:
One month after the 3-dose infant series (7 months of age) and the toddler dose (16 months of age)
Reported as:
Geometric mean · EU/mL
Geometric Mean Antibody Concentrations (GMC) for Pertussis in 13vPnC Group Relative to 7vPnC Group After the 3-dose Infant Series and the Toddler Dose
EU/mL13vPnC After Infant Series Dose 37vPnC After Infant Series Dose 313vPnC After the Toddler Dose7vPnC Afte the Toddler Dose
Pertussis PT51.51 (47.94 to 55.34)50.13 (46.80 to 53.70)36.13 (32.84 to 39.74)36.01 (32.94 to 39.37)
Pertussis FHA179.04 (165.34 to 193.87)166.77 (155.20 to 179.20)347.96 (316.46 to 382.59)345.89 (315.14 to 379.65)
Pertussis PRN141.39 (129.66 to 154.17)135.06 (123.56 to 147.63)232.96 (211.42 to 256.69)261.58 (237.29 to 288.36)
Statistical analysis
  • 13vPnC After Infant Series Dose 3 vs 7vPnC After Infant Series Dose 3 · Ratio: 1.03 · 95% CI 0.93 to 1.13
  • 13vPnC After Infant Series Dose 3 vs 7vPnC After Infant Series Dose 3 · Ratio: 1.07 · 95% CI 0.96 to 1.20
  • 13vPnC After Infant Series Dose 3 vs 7vPnC After Infant Series Dose 3 · Ratio: 1.05 · 95% CI 0.92 to 1.18
  • 13vPnC After the Toddler Dose vs 7vPnC Afte the Toddler Dose · Ratio: 1.00 · 95% CI 0.88 to 1.14
  • 13vPnC After the Toddler Dose vs 7vPnC Afte the Toddler Dose · Ratio: 1.01 · 95% CI 0.88 to 1.15
  • 13vPnC After the Toddler Dose vs 7vPnC Afte the Toddler Dose · Ratio: 0.89 · 95% CI 0.78 to 1.02
PrimaryPercentage of Participants Achieving Antibody Level ≥ 0.35 Microgram Per Milliliter (μg/mL) in 13vPnC Group After the Second Dose and After the Third Dose of a 3-Dose Infant Series and After the Toddler Dose

Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes, present in both 13vPnC and 7vPnC (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age)
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Antibody Level ≥ 0.35 Microgram Per Milliliter (μg/mL) in 13vPnC Group After the Second Dose and After the Third Dose of a 3-Dose Infant Series and After the Toddler Dose
Percentage of Participants13vPnC After Infant Series Dose 213vPnC After Infant Series Dose 313vPnC After the Toddler Dose
Common Serotype - Serotype 496.7 (93.7 to 98.5)98.9 (96.8 to 99.8)99.2 (97.0 to 99.9)
Common Serotype - Serotype 6B57.3 (51.1 to 63.3)98.5 (96.2 to 99.6)99.6 (97.6 to 100.0)
Common Serotype - Serotype 9V91.9 (88.1 to 94.9)99.3 (97.4 to 99.9)100.0 (98.5 to 100.0)
Common Serotype - Serotype 1498.5 (96.3 to 99.6)97.4 (94.7 to 99.0)100.0 (98.4 to 100.0)
Common Serotype - Serotype 18C91.8 (87.8 to 94.8)98.1 (95.7 to 99.4)99.6 (97.7 to 100.0)
Common Serotype - Serotype 19F97.8 (95.2 to 99.2)99.3 (97.3 to 99.9)99.6 (97.6 to 100.0)
Common Serotype - Serotype 23F68.1 (62.0 to 73.7)94.6 (91.1 to 97.0)99.1 (96.9 to 99.9)
Additional Serotype - Serotype 196.3 (93.2 to 98.2)99.3 (97.3 to 99.9)98.7 (96.3 to 99.7)
Additional Serotype - Serotype 388.0 (83.5 to 91.7)90.3 (86.1 to 93.5)92.2 (88.1 to 95.2)
Additional Serotype - Serotype 587.4 (82.7 to 91.1)97.3 (94.6 to 98.9)99.1 (96.9 to 99.9)
Additional Serotype - Serotype 6A84.4 (79.5 to 88.5)97.4 (94.7 to 98.9)99.1 (97.0 to 99.9)
Additional Serotype - Serotype 7F98.5 (96.2 to 99.6)100.0 (98.6 to 100.0)98.8 (96.4 to 99.7)
Additional Serotype - Serotype 19A98.1 (95.7 to 99.4)99.6 (97.9 to 100.0)100.0 (98.4 to 100.0)
Statistical analysis
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 2.2 · 95% CI 0.1 to 4.4
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 41.2 · 95% CI 34.9 to 46.9
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 7.3 · 95% CI 4.1 to 10.4
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: -1.1 · 95% CI -3.4 to 1.2
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 6.4 · 95% CI 3.1 to 9.5
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 1.5 · 95% CI -0.4 to 3.4
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 26.5 · 95% CI 20.7 to 31.9
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 3.0 · 95% CI 0.8 to 5.1
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 2.2 · 95% CI -1.8 to 6.3
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 10.0 · 95% CI 5.9 to 13.9
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 13.0 · 95% CI 8.6 to 17.2
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 1.5 · 95% CI -0.1 to 3.1
  • 13vPnC After Infant Series Dose 2 vs 13vPnC After Infant Series Dose 3 · Difference: 1.5 · 95% CI -0.4 to 3.4

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC Infant Series—16/314 (5.1%)151/314 (48.1%)
7vPnC Infant Series—16/300 (5.3%)156/300 (52%)
13vPnC Post-Infant Series—16/314 (5.1%)7/314 (2.2%)
7vPnC Post-Infant Series—16/300 (5.3%)10/300 (3.3%)
13vPnC Toddler Series—3/291 (1%)124/291 (42.6%)
7vPnC Toddler Series—1/284 (0.4%)110/284 (38.7%)
13vPnC 6-Month Follow-up—3/312 (1%)3/312 (1%)
7vPnC 6-Month Follow-up—6/299 (2%)2/299 (0.7%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
Event13vPnC Infant Series7vPnC Infant Series13vPnC Post-Infant Series7vPnC Post-Infant Series13vPnC Toddler Series7vPnC Toddler Series13vPnC 6-Month Follow-up7vPnC 6-Month Follow-up
Induration (Moderate)Skin and subcutaneous tissue disorders12/2474/24816/13616/124————
BronchiolitisInfections and infestations6/3146/3000/3140/3000/2910/2840/3120/299
Urinary tract infectionInfections and infestations0/3144/3001/3140/3000/2910/2840/3120/299
Respiratory syncytial virus bronchiolitisInfections and infestations4/3141/3000/3141/3000/2910/2840/3120/299
Febrile convulsionNervous system disorders0/3141/3001/3141/3000/2910/2840/3122/299
BronchitisInfections and infestations2/3141/3001/3142/3000/2910/2840/3121/299
GastroenteritisGastrointestinal disorders1/3142/3000/3141/3000/2910/2842/3120/299
PyrexiaGeneral disorders1/3142/3000/3140/3000/2910/2840/3121/299
Gastroenteritis rotavirusGastrointestinal disorders0/3140/3002/3140/3001/2910/2840/3121/299
Arthritis bacterialInfections and infestations0/3140/3000/3140/3000/2911/2840/3120/299
Most frequent other events
Showing 10 of 146
Most frequent other events
Event13vPnC Infant Series7vPnC Infant Series13vPnC Post-Infant Series7vPnC Post-Infant Series13vPnC Toddler Series7vPnC Toddler Series13vPnC 6-Month Follow-up7vPnC 6-Month Follow-up
Tenderness (Any)Skin and subcutaneous tissue disorders136/275117/270——124/193110/170——
IrritabilityGeneral disorders151/234150/244——————
IrritabilityGeneral disorders142/276114/267——113/183105/170——
IrritabilityGeneral disorders131/229130/221——————
Increased sleepGeneral disorders146/273138/269——63/16051/145——
Decreased appetiteGeneral disorders107/26995/258——93/17470/147——
Tenderness (Any)Skin and subcutaneous tissue disorders104/21790/215——————
Decreased appetiteGeneral disorders103/21987/204——————
Increased sleepGeneral disorders102/21892/221——————
Tenderness (Any)Skin and subcutaneous tissue disorders103/227108/232——————

Baseline characteristics

Age Continuous
Age Continuous(months)13vPnC7vPnCTotal
Mean2.1 ± 0.52.1 ± 0.52.1 ± 0.5
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC7vPnCTotal
Female148152300
Male167152319
08

Study locations

41 sites
  • Ferrol, A Coruna 15405, Spain
  • Santiago de Compostela, A Coruna 15706, Spain
  • Argentona, Barcelona 08310, Spain
  • Sabadell, Barcelona 08208, Spain
  • Sant Adria de Besos, Barcelona 08930, Spain
  • Sant Cugat del Valles, Barcelona 08195, Spain
  • Sant Cugat del Valles, Barcelona 08197, Spain
  • Bilbao, Bizkaia 48013, Spain
  • Burela, Lugo 27880, Spain
  • Alcorcon, Madrid 28922, Spain
  • Fuenlabrada, Madrid 28943, Spain
  • Getafe, Madrid 28900, Spain
  • Getafe, Madrid 28902, Spain
  • Mostoles, Madrid 28937, Spain
  • Parla, Madrid 28980, Spain
  • Antequera, Malaga 29200, Spain
  • Pamplona, Navarra 31008, Spain
  • Vigo, Pontevedra 36204, Spain
  • Burjassot, Valencia 46110, Spain
  • La Eliana, Valencia 46183, Spain
  • Quart de Poblet, Valencia 46930, Spain
  • A Coruna, 15006, Spain
  • Almeria, 04007, Spain
  • Almeria, 04009, Spain
  • Almeria, 04120, Spain
  • Barcelona, 08017, Spain
  • Barcelona, 08025, Spain
  • La Coruna, 15270, Spain
  • Madrid, 28021, Spain
  • Madrid, 28041, Spain
  • Malaga, 29015, Spain
  • Ourense, 32005, Spain
  • Sevilla, 41013, Spain
  • Valencia, 46008, Spain
  • Valencia, 46011, Spain
  • Valencia, 46013, Spain
  • Valencia, 46021, Spain
  • Valencia, 46022, Spain
  • Valencia, 46023, Spain
  • Valencia, 46024, Spain
  • Valencia, 46200, Spain
09

References and documents

Publications

  • Rodgers GL, Esposito S, Principi N, Gutierrez-Brito M, Diez-Domingo J, Pollard AJ, Snape MD, Martinon-Torres F, Gruber WC, Patterson S, Thompson A, Gurtman A, Paradiso P, Scott DA. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule. Vaccine. 2013 Oct 1;31(42):4765-74. doi: 10.1016/j.vaccine.2013.08.009. Epub 2013 Aug 16. PubMed 23965217 ↗
  • Gimenez-Sanchez F, Kieninger DM, Kueper K, Martinon-Torres F, Bernaola E, Diez-Domingo J, Steul K, Juergens C, Gurtman A, Giardina P, Liang JZ, Gruber WC, Emini EA, Scott DA; 501 and 006 study groups. Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine. Vaccine. 2011 Aug 11;29(35):6042-8. doi: 10.1016/j.vaccine.2011.06.026. Epub 2011 Jun 23. PubMed 21704105 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 4 years 1 month after primary completion. A results delay was requested in Feb 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2006
First posted
Aug 29, 2006
Start
Oct 2006
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results delay requested
Feb 26, 2009
Results first posted
Aug 16, 2012
Last update
Aug 16, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00368966
Responsible party
Sponsor
First posted
Aug 29, 2006
Start date
Oct 2006
Primary completion
Jul 2008
Completion
Jul 2008
Results posted
Aug 16, 2012
Last update
Aug 16, 2012

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
Trial Manager
principal investigator · For Spain, infomed@wyeth.com
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion